Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaginal interleukin measurement in cervical intraepithelial neoplasia or chronic recurrent vaginal candidiasis treated with 4-phenylbutyrate
2010-021502-38Phase 2Terminated
- Sponsor
- Christine Fromer Stiftung
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of sodium phenylbutyrate in cervical intraepithelial neoplasia (CIN) and vulvovaginal candidiasis (VVC), sponsored by Christine Fromer Stiftung. Primary endpoint: Change in vaginal interleukin levels. Started Nov 2010; status: terminated.
02
Drugs
sodium phenylbutyrate
03
Conditions
cervical intraepithelial neoplasia (CIN)vulvovaginal candidiasis (VVC)
Beyond the preview
Go deeper on 2010-021502-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021502-38.